BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chighizola CB, Ubiali T, Meroni PL. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches. J Immunol Res 2015;2015:951424. [PMID: 26075289 DOI: 10.1155/2015/951424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Byambajav T, Waki T, Miura K, Tanaka-Mizuno S. Association between adherence to warfarin and thrombotic events in patients with antiphospholipid syndrome in Japan: A claims-based retrospective cohort study. Pharmacoepidemiol Drug Saf 2021. [PMID: 34382707 DOI: 10.1002/pds.5343] [Reference Citation Analysis]
2 de Oliveira Vaz C, de Moraes Mazetto Fonseca B, Nascimento Silva Vasconcelos PE, Brito Bastos L, Cursino MA, Coelho França Quintanilha J, Tripiquia Vechiatto Mesquita GL, Rosa Dos Santos AP, Cardoso Jacintho B, Oliveira JD, Annichino-Bizzachi J, Andrade Orsi F. Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist. Lupus 2021;30:707-14. [PMID: 33509064 DOI: 10.1177/0961203321990079] [Reference Citation Analysis]
3 Cheng C, Cheng GY, Denas G, Pengo V. Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. Blood Rev 2021;48:100788. [PMID: 33341301 DOI: 10.1016/j.blre.2020.100788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2020;10:CD012169. [PMID: 33045766 DOI: 10.1002/14651858.CD012169.pub3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Mahdian S, Zarrabi M, Moini A, Movahedi M, Shahhoseini M. In silico identification of new inhibitors for βeta-2-glycoprotein I as a major antigen in antiphospholipid antibody syndrome. J Mol Model 2020;26:156. [PMID: 32458176 DOI: 10.1007/s00894-020-04406-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mazzoccoli C, Comitangelo D, D'Introno A, Mastropierro V, Sabbà C, Perrone A. Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations. Auto Immun Highlights 2019;10:9. [PMID: 32257065 DOI: 10.1186/s13317-019-0119-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cáliz Cáliz R, Díaz Del Campo Fontecha P, Galindo Izquierdo M, López Longo FJ, Martínez Zamora MÁ, Santamaría Ortiz A, Amengual Pliego O, Cuadrado Lozano MJ, Delgado Beltrán MP, Carmona Ortells L, Cervantes Pérez EC, Díaz-Cordovés Rego G, Garrote Corral S, Fuego Varela C, Martín López M, Nishishinya B, Novella Navarro M, Pereda Testa C, Sánchez Pérez H, Silva-Fernández L, Martínez Taboada VM. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment. Reumatol Clin (Engl Ed) 2020;16:71-86. [PMID: 30713012 DOI: 10.1016/j.reuma.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Högdén A, Antovic A, Berg E, Bremme K, Chaireti R. Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. Lupus 2019;28:868-77. [DOI: 10.1177/0961203319852155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Schofield JR, Palestine AG, Pelak V, Mathias MT. Deep capillary retinal ischemia and high-titer prothrombin-associated antiphospholipid antibodies: A case series of three patients. Am J Ophthalmol Case Rep 2019;14:105-9. [PMID: 31011663 DOI: 10.1016/j.ajoc.2019.03.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Arcadi FA, Portaro S, Giorgianni R, Naro A, Casella C, Genovese C, Marino S, Calabrò RS. New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report. Medicina (Kaunas) 2019;55:E71. [PMID: 30884868 DOI: 10.3390/medicina55030071] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Goldman-Mazur S, Wypasek E, Karpiński M, Stanisz A, Undas A. High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. Thromb Res 2019;176:67-73. [PMID: 30780006 DOI: 10.1016/j.thromres.2019.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Kuznetsova IV. Role ofpreconception endothelial dysfunction in development of obstetric complications. Medicinskij alfavit 2019;1:53-8. [DOI: 10.33667/2078-5631-2019-1-1(376)-53-58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wincup C, Ioannou Y. The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. Front Pediatr 2018;6:362. [PMID: 30542645 DOI: 10.3389/fped.2018.00362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
14 Antovic A, Sennström M, Bremme K, Svenungsson E. Obstetric antiphospholipid syndrome. Lupus Sci Med 2018;5:e000197. [PMID: 30364418 DOI: 10.1136/lupus-2016-000197] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
15 Varner CK, Marquardt CW, Pickens PV. Antiphosphatidylserine Antibody as a Cause of Multiple Dural Venous Sinus Thromboses and ST-Elevation Myocardial Infarction. Am J Case Rep 2018;19:1042-6. [PMID: 30166503 DOI: 10.12659/AJCR.909698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Grygiel-Górniak B, Limphaibool N, Puszczewicz M. Clinical implications of systemic lupus erythematosus without and with antiphospholipid syndrome in peri- and postmenopausal age. Prz Menopauzalny 2018;17:86-90. [PMID: 30150916 DOI: 10.5114/pm.2018.77308] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Micallef S, Mallia Azzopardi C. Antiphospholipid syndrome masquerading as a case of infective endocarditis. BMJ Case Rep 2018;2018:bcr-2018-224404. [PMID: 29866682 DOI: 10.1136/bcr-2018-224404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chighizola CB, Meroni PL. Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. Curr Rheumatol Rep 2018;20:44. [PMID: 29850957 DOI: 10.1007/s11926-018-0741-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Nalli C, Somma V, Andreoli L, Büttner T, Schierack P, Mahler M, Roggenbuck D, Tincani A. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights 2018;9:6. [PMID: 29845583 DOI: 10.1007/s13317-018-0106-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Gabbay-Benziv R, Zafrir-Danieli H, Blickstein D, Shmueli A, Salman L, Hadar E. Antiphospholipid syndrome characteristics and adverse pregnancy outcomes after 20 weeks of pregnancy. Int J Gynaecol Obstet 2018;142:214-20. [PMID: 29676461 DOI: 10.1002/ijgo.12511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Schofield JR. Autonomic neuropathy-in its many guises-as the initial manifestation of the antiphospholipid syndrome. Immunol Res 2017;65:532-42. [PMID: 28116654 DOI: 10.1007/s12026-016-8889-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. J Autoimmun 2018;90:1-27. [PMID: 29449131 DOI: 10.1016/j.jaut.2018.02.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
23 Okano M, Nakayama K, Tamada N, Shinkura Y, Yanaka KI, Onishi H, Tanaka H, Shinke T, Tanaka H, Okita Y, Emoto N, Hirata KI. Reversible Parkinsonism and Multiple Cerebral Infarctions after Pulmonary Endarterectomy in a Patient with Antiphospholipid Syndrome. Intern Med 2018;57:2019-23. [PMID: 29321405 DOI: 10.2169/internalmedicine.9880-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2017;10:CD012169. [PMID: 28968483 DOI: 10.1002/14651858.CD012169.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
25 Rand JH, Wu XX, Wolgast LR, Lei V, Conway EM. A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 2017;156:119-25. [PMID: 28628799 DOI: 10.1016/j.thromres.2017.06.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kolyada A, Barrios DA, Beglova N. Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops. Antibodies (Basel) 2017;6:8. [PMID: 28748111 DOI: 10.3390/antib6020008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Arboix A, Jiménez C, Massons J, Parra O, Besses C. Hematological disorders: a commonly unrecognized cause of acute stroke. Expert Review of Hematology 2016;9:891-901. [DOI: 10.1080/17474086.2016.1208555] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
28 Marcantoni C, Emmanuele C, Scolari F. Renal involvement in primary antiphospholipid syndrome. J Nephrol 2016;29:507-15. [PMID: 27198137 DOI: 10.1007/s40620-016-0317-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Watura C, Shawe D, Hacking N. Uterine Artery Embolization Resulting in Catastrophic Antiphospholipid Syndrome in a Patient with Primary Antiphospholipid Syndrome. J Vasc Interv Radiol 2016;27:764-6. [PMID: 27106650 DOI: 10.1016/j.jvir.2015.11.052] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Chighizola CB, Raschi E, Banzato A, Borghi MO, Pengo V, Meroni PL. The challenges of lupus anticoagulants. Expert Rev Hematol 2016;9:389-400. [PMID: 26789237 DOI: 10.1586/17474086.2016.1140034] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
31 Gerosa M, Meroni PL, Erkan D. Recognition and management of antiphospholipid syndrome. Current Opinion in Rheumatology 2016;28:51-9. [DOI: 10.1097/bor.0000000000000240] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]